I
CRDF icon

INVST’s Cardiff Oncology CRDF Stock Holding History

INVST’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.6K Buy
40,500
+4,500
+13% +$9.24K 0.01% 328
2025
Q4 		$101K Sell
36,000
-4,500
-11% -$10.4K 0.01% 302
2025
Q3 		$83.4K Buy
40,500
+4,500
+13% +$12.4K 0.01% 302
2025
Q2 		$113K Hold
36,000
– – 0.01% 292
2025
Q1 		$113K Hold
36,000
– – 0.02% 266
2024
Q4 		$156K Buy
36,000
+13,500
+60% +$42.2K 0.02% 242
2024
Q3 		$60.1K Sell
22,500
-13,500
-38% -$31.9K 0.01% 247
2024
Q2 		$73.8K Buy
+36,000
New +$136K 0.01% 258

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

INVST's CRDF Position: Q1 2026 in Review

INVST increased its Cardiff Oncology (CRDF) stake by 13% in Q1 2026, buying an estimated $9.24K and bringing the position to 40,500 shares worth $65.6K. The position accounts for 0.01% of the portfolio, ranked #328.

INVST first reported a position in CRDF in Q2 2024 and has held it in 8 quarters since. The position peaked at $156K in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • INVST held 40,500 shares of Cardiff Oncology worth $65.6K as of Q1 2026.
  • INVST bought 4,500 Cardiff Oncology shares in Q1 2026, an estimated $9.24K.
  • Cardiff Oncology made up 0.01% of INVST's portfolio in Q1 2026, its #328 holding.
  • INVST first reported a position in Cardiff Oncology in Q2 2024 and has held it in 8 quarters since.
  • INVST's Cardiff Oncology position peaked at $156K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on INVST's 13F filing for Q1 2026, filed 13 May 2026.